Organization, Basis of Presentation and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2023

Schedule of Fair Values of Financial Instruments

Marizyme measures the following financial instruments at fair value on a recurring basis. At December 31, 2023 and 2022, the fair values of these financial instruments were as follows:

December 31, 2023	Level 1		Level 2		Level 3
	Fair Value Hierarchy
December 31, 2023	Level 1		Level 2		Level 3
Liabilities
Derivative liabilities	$	-	$	-	$	-
Contingent liabilities		-		-		5,406,000
Total	$	-	$	-	$	5,406,000

December 31, 2022	Level 1		Level 2		Level 3
	Fair Value Hierarchy
December 31, 2022	Level 1		Level 2		Level 3
Liabilities
Derivative liabilities	$	-	$	-	$	4,823,725
Contingent liabilities		-		-		9,707,000
Total	$	-	$	-	$	14,530,725

Schedule of Liabilities Fair Value Measured

The following table provides a roll forward of all liabilities measured at fair value using Level 3 significant unobservable inputs:

Derivative and Contingent Liabilities	Derivative Liabilities			Contingent Liabilities
Balance at December 31, 2022	$	4,823,725		$	9,707,000
Change in fair value of contingent liabilities		-			(4,301,000	)
Derivative liabilities extinguished pursuant to Unit Purchase Agreement (Note 6)		(4,823,725	)		-
Derivative liabilities issued pursuant to OID Purchase Agreement (Note 6)		12,292,635			-
Change in fair value of derivative liabilities		(795,934	)		-
Derivative liabilities reclassified to equity (Note 6)		(11,496,701	)
Balance at December 31, 2023	$	-		$	5,406,000

MARIZYME, INC. 10-K